JørgensenJT. Oncology drug-companion diagnostic combinations. Cancer Treatment and Research Communications. 2021; 29:100492. doi:10.1016/j.ctarc.2021.100492
2.
AkhmetovI, BubnovRv. Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine. EPMA Journal. 2015; 6(1). doi:10.1186/s13167-015-0041-3
3.
FarkasN. A 90-Minute Guide to Defi Ne, Demonstrate and Capture Diagnostics Value Confi Dently.; 2021.
4.
SireciAN, PatelJL, JosephL, et al.Molecular Pathology Economics 101: An Overview of Molecular Diagnostics Coding, Coverage, and Reimbursement: A Report of the Association for Molecular Pathology. Journal of Molecular Diagnostics. 2020; 22(8):975–993. doi:10.1016/j.jmoldx.2020.05.008
MoseleF, RemonJ, MateoJ, et al.Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology. 2020; 31(11):1491–1505. doi:10.1016/j.annonc.2020.07.014
11.
GovaertsL, SimoensS, van DyckW, HuysI. Shedding Light on Reimbursement Policies of Companion Diagnostics in European Countries. Value in Health. 2020; 23(5):606–615. doi:10.1016/j.jval.2020.01.013
